** Revolution Medicines is seeking a Vice President, Lifecycle Leader for their daraxonrasib Lung Cancer program, accountable for the global lifecycle strategy from development through commercialization. The ideal candidate will possess extensive experience in oncology commercialization, particularly with new molecular entity (NME) launches. **
Base: $294,000—$367,000 USD; Bonus/Equity: Not specified; Benefits: Not specified
Must-have
Nice-to-have
Not specified